Facilities & Capacity

Forge Bio bags $90m funding to expand CGT capabilities

CDMO Forge Biologics has completed a $90 million Series C financing round, which will be used to expand its technologies, manufacturing systems, and cell lines. The gene therapy contract development manufacturing organization (CDMO) Forge Bio has raised $90 million with finances led by Aisling Capital, Drive Capital, and an undisclosed strategic investor. According to the CDMO, it will expand the number of its service offerings available to customers in order to scale its gene therapy programs from research to clinical…

Rubius weighs up RI plant sale as part of pipeline restructure

Rubius Therapeutics will also cut 75% of its staff as it discontinues its solid tumor programs in favor of developing a next-generation red blood cell-based cell conjugation platform. Massachusetts-based Rubius announced yesterday it is scrapping clinical programs RTX-240 and RTX-224 for solid tumors and instead focusing on improving the efficacy of the tech platform they were based on. “Following careful review of recent technical progress in an alternative format for making Red Cell Therapeutics, we believe that this process has…

Novartis looks beyond mAbs with $270m manufacturing spending spree

Novartis is making a multi-year investment across three European manufacturing sites to support a growing early-stage pipeline of next-generation biologics. Pharma giant Novartis announced the investments this week, with facilities in Switzerland, Slovenia, and Austria set to see increased drug substance and drug product capabilities. Specifically, $110 million will be injected in clinical manufacturing and technical development capabilities at the firm’s Mengeš, Slovenia site, while $60 million will be used to add technical manufacturing capacity at the Schaftenau campus in…

Orca Bio taking inhouse approach to cell therapy with Sacramento plant

“It’s important we maintain control over the process to ensure we are meeting the highest standards of quality,” says cell therapy developer Orca as it announces a 100,000 square-foot plant. Orca Bio’s lead product, the cell therapy Orca-T, is in Phase III clinical trials for several of the most prevalent blood cancers. As such, the firm is looking beyond its clinical manufacturing site in Sacramento, California and is constructing a 100,000 square-foot commercial facility nearby with the capacity to manufacture…

Biotimize looks to build first biological CDMO in Brazil

Biotimize has opened a $30 million Series A funding round and says the investment will allow the firm to build the first biological CDMO in Brazil. Biotimize, a growth-stage biotechnology as a service (BaaS) firm, claims its fundraising round – if successful – will enable it to build the first biological contract development manufacturing organization (CDMO) facility in Brazil, which they claim will make it the first end-to-end biological CDMO in South America. The city of Piracicaba (about 100km northwest…

Horizon doubling down on Irish biomanufacturing with drug substance plant

Horizon Therapeutics will build a second facility in Waterford, Ireland to support its rare disease biologics portfolio. In June 2021, Horizon acquired a 44,000 square-foot drug product manufacturing facility from OPKO health’s EirGen Pharma for $65 million. This first step into building a biomanufacturing network for horizon followed the launch of Tepezza (teprotumumab), a monoclonal antibody for thyroid eye disease, and off the back of growing sales of gout treatment Krystexxa (pegloticase). Having tested the waters, the firm will now…

TCR² lauds positive work culture to overcome staff bottlenecks

T-cell receptor firm TCR² Therapeutics told delegates at Advanced Therapies Europe it is key to embed culture into your employees to attract and retain talent in the life science space. Angela Justice, chief people officer at TCR², told attendees that the key three ways to scale your culture lie in “anchor[ing] your culture through the employee life cycle, focus[ing] on retention, and find[ing] your force multipliers.’ Justice noted that a challenge of anchoring culture typically derives from the values of…

ElevateBio inks deal with Pittsburgh University to accelerate CGTs

ElevateBio will use its development and manufacturing platform, BaseCamp, to support the University of Pittsburgh’s cell and gene therapy (CGT) pipeline. The long-term partnership between ElevateBio and the University of Pittsburgh aims to develop CGTs through the implementation of viral vector and cell therapy process development and manufacturing platform, BaseCamp. BaseCamp is designed for both commercial and clinical cell and gene therapies as well as regenerative medicines.  And according to ElevateBio, the University of Pittsburgh will be fully equipped with…

Cytiva and ForecyteBio partner to advance CGTs

Cytiva claims the installation of its FlexFactory facilities will provide ForecyteBio with access to platforms to manufacture viral vectors and plasmid DNA for the US and Chinese markets. Cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) ForcecyteBio will begin the collaboration at Cytiva’s Fast Trak center located in Shanghai, China. “Cytiva‘s Fast Trak Center will consult on process design and development, GMP production platform development, and talent building and training,” a spokesperson for Cytiva told BioProcess Insider.…

Beyond the peak: Catalent prepped for two-third cut in COVID revenues

Increased cell and gene therapy, drug product, and drug substance demand will offset the considerable decline in COVID-19 revenues in FY 2023, says CDMO Catalent. The contract development and manufacturing organization (CDMO) reported its results this week, with its Biologics division – which represents over 50% of its business – pulling in $667 million in Q4 (up 14% year-on-year) and $2.55 billion for the full fiscal year 2022 (up 34%). Catalent’s Biologics segment includes the development and manufacturing for biologic…